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Background: The aim of the present analysis
from the epidemiologic international day for the
evaluation of patients at risk for venous throm-
boembolism (VTE) in the acute hospital care set-
ting (ENDORSE) study was to evaluate the
prevalence of VTE risk in acute care hospitals and
the proportion of at-risk medical and surgical pa-
tients who receive recommended prophylaxis in
Switzerland.
Methods: All patients (age ≥40 years) admitted
to a medical ward or those (age ≥18 years) admit-
ted to a surgical ward in ten randomly selected
Swiss hospitals were assessed for risk of VTE.
The 2004 American College of Chest Physicians
(ACCP) evidence-based consensus guidelines
were used to assess VTE risk and to determine
whether patients were receiving recommended
thromboprophylaxis.
Results: 2000 patients were eligible; of these
1153 (58%) were in surgical wards, and 847
(42%) in medical wards. According to the ACCP
criteria, the proportion of surgical patients at
VTE risk was similar in Switzerland (68%, be-
tween hospital range 48–86%) in comparison to
the global ENDORSE study (64%) (p = 0.296).
The rate of at-risk medical patients was lower in
Switzerland (21%, range 3–44%) than in the
global study (42%) (p <0.001). The proportion of
at-risk surgical patients with ACCP-recom-
mended VTE prophylaxis was higher in Switzer-
land (81%, between-hospital range 76–93%) than
in the global study (59%) (p <0.001). Among
medical patients at risk, the use of recommended
thromboprophylaxis was higher in Switzerland
(61%, between-hospital range 0–84%) than in the
global ENDORSE (40%) (p <0.001). However
56% of the patients with cancer, 41% with major
trauma, and 29% undergoing vascular surgery did
not receive any recommended prophylaxis.
Among surgical patients at risk, the use of ACCP-
recommended prophylaxis was lower in academic
(77%) vs. non-academic (86%) institutions (p =
0.0025).
Conclusions: In Switzerland, although the rate
of recommended thromboprophylaxis is higher
than in many countries, it is still improvable in
medical patients at risk according to the ACCP
guidelines. Consequently, hospital wide strategies
for systematic risk factor assessment and imple-
mentation of practical tools to ensure appropriate
use of prophylaxis in patients at VTE risk are re-
quired.
Key words: venous thromboembolism; thrombo-
prophylaxis; hospitalised medical and surgical patients
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Introduction
Venous thromboembolism (VTE) accounts
for more than 500000 deaths in Europe and over
200 thousand fatalities in the United States annu-
ally [1–2]. Among hospitalised patients, 5–10% of
all deaths are due to pulmonary embolism (PE)
[3]. In addition to the acute risk of mortality, VTE
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is associated with long-term risks of post-throm-
botic syndromeand chronic thromboembolic pul-
monary hypertension [4–5].These complications
contribute substantially to patient morbidity and
the cost of management. Pharmacological and
mechanical types of prophylaxis can prevent VTE
effectively [6–7].
The American College of Chest Physicians
(ACCP) evidence-based consensus guidelines for
VTE prophylaxis released in 2004 [8] were
adapted to local practice by the Swiss Expert
Group [9]. Previously, an observational study
conducted in 2003 in eight large hospitals across
Switzerland showed that 59% of hospitalised
medical patients were at risk for VTE and re-
ported a 50% underuse of thromboprophylaxis
[10]. The proportion of at-risk surgical patients
who receive prophylaxis in Switzerland is un-
known.
The present analysis from the multinational,
observational, cross-sectional epidemiologic in-
ternational day for the evaluation of patients at
risk for venous thromboembolism in the acute
hospital care setting (ENDORSE) study [11],
aims to assess the prevalence of risk for VTE in
hospitalised medical and surgical patients in
Switzerland, determine the proportion of at-risk
patients who received the ACCP recommended
prophylaxis, and relate the Swiss and global re-
sults of this survey.
Methods and patients
Swiss hospitals with more than 50 beds were eligible
for participation in the ENDORSE study if they pro-
vided acute medical care and major surgery. Ten partici-
pating hospitals were randomly chosen from the official
list of Swiss acute health care providers. Ethics committee
approval was received for each participating hospital ac-
cording to national and local regulations.
All patients ≥18 years in eligible surgical wards or
≥40 years in eligible medical wards were screened. Pa-
tients were included if they were hospitalised on the pre-
specified day of the cross-sectional survey. Patient demo-
graphics, admission and post-admission diagnoses, VTE
risk factors, bleeding risk factors, duration of stay, and ini-
tiation, duration and type of VTE prophylaxis were col-
lected on that pre-specified day from a review of hospital
charts in all eligible wards at each hospital. The data col-
lection was performed by trained external data abstractors
using standard case report forms and covered the period
from the day of hospital admission to the pre-specified
day of chart review. Patients with unavailable charts or
those who were admitted for the treatment of acute VTE
were excluded.
The 2004 ACCP guidelines were used to assess the
risk for VTE, proportion of at-risk patients receiving rec-
ommended thromboprophylaxis, and risk for bleeding
presenting a contraindication to pharmacological pro-
phylaxis, as specified in the methodology section of the
global ENDORSE study publication [11].
Statistical analysis
Categorical data are presented as numbers and per-
centages of the population, and quantitative data as medi-
ans and interquartile ranges (IQR). Hospital rates were
calculated from individual patient data. A minimum of
369 patients was needed to assess the occurrence of VTE
risk at 60% with an error margin of 5%. Group compar-
isons were performed using the Fisher exact test, and all
reported p-values are two-tailed. SAS version 9.1 was
used for statistical analyses.
Role of the funding source
The study protocol was written by an independent
scientific steering committee. Data collection was co-or-
dinated by the Center for Outcomes Research (Univer-
sity of Massachusetts Medical School, Worcester, MA,
USA). All statistical analyses were performed by the Cen-
ter for Outcomes Research.
Results
The present analysis was performed on the
ENDORSE study patients recruited in Switzer-
land. In October 2006, all eligible patients from
ten randomly selected Swiss hospitals were en-
rolled. Two (20%) hospitals were categorised as
academic, two (20%) as private, and three (30%)
were localised in the French speaking part of
Switzerland.The median number of beds per hos-
pital was 200 (range across participating hospitals
58–494 beds). The number of beds assessed, rea-
sons for exclusion from assessment and the num-
ber of assessable hospitalised patients are shown
in figure 1.
2000 Swiss patients were eligible; of these
1153 (58%) were in surgical, and 847 (42%) in
medical wards. Patient characteristics are sum-
marised in table 1. According to the ACCP crite-
ria, the proportion of surgical patients at VTE
risk was similar in Switzerland (68%, between-
hospital range 48–86%) in comparison to the
Patients all surgical medical
N = 2000 N = 1153 N = 847
Female sex, n (%) 930 (47) 513 (44) 417 (49)
Age (years), median (IQR) 68 (55–78) 66 (60–76) 70 (59–79)
Body mass index (kg/m
2
), median (IQR) 26 (23–29) 26 (23–29) 25 (22–29)
Length of hospital stay up to survey date (days), 6 (2–11) 5 (2–11) 6 (2–12)
median (IQR)
IQR: Interquartile range.
Table 1
Patient characteristics.
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global ENDORSE study (64%) (p = 0.296). The
rate of at-risk medical patients was lower in
Switzerland (21%, range 3–44%) than in the
global study (42%) (p <0.001). Among the pa-
tients with risk factors for VTE, median age was
68 (IQR 54–77) years, 45% were women and me-
dian BMI was 26 (IQR 23–29) kg/m
2
. Before hos-
pitalisation, the most common VTE risk factors
were chronic heart failure (31%) and chronic pul-
monary disease (25%) in medical patients, and
obesity (15%) and chronic heart failure (11%) in
surgical patients (table 2).The most common post
admission risk factors for VTE in both patient
populations were either complete immobilisation
or immobilisation with bathroom privileges
(28%) and admission to an intensive or critical
care unit (21%).
The proportion of at-risk surgical patients
with ACCP-recommended VTE prophylaxis was
higher in Switzerland (81%, between-hospital
range 76–93%) than in the global study (59%) (p
<0.001). Among medical patients at risk, the use
of recommended thromboprophylaxis was higher
in Switzerland (61%, between-hospital range 0–
84%) than in the global ENDORSE (40%) (p
<0.001). The proportion of patients receiving
ACCP recommended prophylaxis varied between
different types of surgery, ranging from 71% of
patients undergoing vascular operations to 100%
of patients undergoing curative arthroscopy (table
3). 59% of patients with major trauma not under-
going any surgery received prophylaxis. The pro-
portion of at-risk medical patients receiving pro-
phylaxis ranged from 40% in patients with en-
docrine/metabolic disease to 88% of patients with
ischaemic stroke (table 3). An additional 19% of
the medical patients received non-recommended
prophylaxis, mainly due to the high prevalence of
patients (16%) with ongoing use of vitamin K an-
tagonists.
Anticoagulants were the most frequently used
form of VTE prophylaxis in the at-risk popula-
tion, low-molecular-weight heparin being the
most commonly prescribed anticoagulant (table
4). Graduated compression stockings were used
more frequently in surgical patients than in med-
ical patients (p <0.001).
Of the population at VTE risk, 13 (7%) med-
ical and 50 (6%) surgical patients were considered
to have a contraindication to pharmacological
Figure 1
Patient sample.
Reasons for Exclusion n %
Missing hospital chart 91 37.4%
Patient refused to give consent 0 0.0%
Too young (age <18 for surgical; age <40 for medical) 99 40.7%
Admitted for treatment of VTE 2 0.8%
Admitted for diagnostic testing (type of ward not specified) 0 0.0%
Minor operation (type of ward not specified) 3 1.2%
Patients should be in excluded wards 8 3.3%
Transfer patients 0 0.0%
Missing key information (birth year, surgery type, etc.) 40 16.5%
4746 Hospital Beds*
2483 Beds in IneligibleWards
2263 Beds in EligibleWards
20 Empty Beds in EligibleWards
2243 Patients in EligibleWards**
243 Patients Excluded:
2000 Evaluable Patients
* Based on Hospital Enrollment Forms
** Based on Patient Enrollment Logs, includes patients who did not meet protocol
Patients at VTE risk all surgical medical
CH global CH global CH global
N = 959 N = 33797 N = 780 N = 18544 N = 179 N = 15253
Risk factors prior to hospital admission
Chronic heart failure, n (%) 137 (15) 5.334 (16) 82 (11) 1.585 (9) 55 (31) 3.749 (25)
Obesity, n (%) 134 (15) 3.619 (11) 111 (15) 1.875 (10) 23 (13) 1.744 (11)
Chronic pulmonary disease, n (%) 111 (12) 5.642 (17) 66 (9) 1.555 (8) 45 (25) 4.087 (27)
Varicose veins or venous insufficiency, n (%) 72 (8) 2.318 (7) 58 (8) 1.308 (7) 14 (8) 1.010 (7)
Previous venous thromboembolism, n (%) 57 (6) 1.216 (4) 45 (6) 466 (3) 12 (7) 750 (5)
Thrombophilia, n (%) 16 (2) 121 (0.4) 15 (2) 48 (0.3) 1 (0.6) 73 (0.5)
Risk factors during hospitalization
Admitted to ICU/CCU, n (%) 204 (21) 8.984 (25) 162 (21) 4.595 (23) 42 (24) 4.389 (28)
Central venous catheter, n (%) 141 (15) 4.861 (14) 130 (17) 3.110 (16) 11 (6) 1.751 (11)
Immobile with bathroom privileges, n (%) 137 (14) 8.924 (25) 107 (14) 4.621 (23) 30 (17) 4.303 (28)
Complete immobilisation, n (%) 131 (14) 12.929 (37) 105 (14) 7.797 (39) 26 (15) 5.132 (33)
Mechanical ventilation, n (%) 101 (11) 3.726 (11) 86 (11) 2.448 (12) 15 (8) 1.278 (8)
Cancer therapy, n (%) 9 (0.9) 385 (1) 4 (0.5) 108 (0.5) 5 (3) 277 (2)
Heparin induced thrombocytopenia, n (%) 1 (0.1) 54 (0.2) 0 (0.0) 25 (0.1) 1 (0.6) 29 (0.2)
More than one condition was allowed per patient. CH: Switzerland.
Table 2
Risk factors for
venous thrombo-
embolism.
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prophylaxis.The most common contraindications
were clinically relevant hepatic impairment and
active gastroduodenal ulcer in medical patients,
and bleeding on admission and clinically relevant
hepatic impairment in surgical patients (table 5).
Of those considered to have a contraindication to
pharmacological prophylaxis, 8 (62%) medical
and 12 (24%) surgical patients received mechani-
cal prophylaxis alone.
Across Switzerland, the proportion of pa-
tients at VTE risk ranged among hospitals from
48% to 86% for surgical patients and from 3% to
44% for medical patients. The proportion of at-
risk patients receiving the ACCP-recommended
prophylaxis varied from 77% to 93% for surgical
patients and from 0% to 84% for medical patients
(table 6). Despite this high between-hospital vari-
ability, no differences in the proportions of pa-
tients at VTE risk were found between academic
and non-academic, public and private and Ger-
man and French speaking hospitals. In contrast,
among surgical patients at risk, the use of ACCP-
recommended prophylaxis was lower in academic
(77%) vs non-academic (86%) institutions (p =
0.0025) (fig. 2), and among medical patients at
risk, prophylaxis use was higher in hospitals lo-
cated in the German (66%) vs French (48%)
speaking part of Switzerland (p = 0.0297).
Discussion
The presented analysis from the ENDORSE
survey shows that in Switzerland, almost half of
all hospitalised patients are at-risk for VTE, and
that surgical patients seem to be more frequently
at-risk than medical patients. Three quarters of
at-risk patients received an ACCP-recommended
method of prophylaxis which compares
favourably with other countries participating in
the global ENDORSE study [11].
In comparison to global ENDORSE study
results [11], the proportion of surgical patients at-
risk for VTE did not largely differ, whereas the
proportion of at-risk medical patients was very
low in Switzerland. Moreover, a previous survey
on hospitalised medical patients in eight large
Swiss hospitals [10] reported rate of VTE risk
more than twice as high compared to our current
observation. A potential explanation for the low
rate of medical patients at VTE risk in our cohort
is the low proportion of patients with immobilisa-
tion, an important risk factor that might have
been underestimated during the data collection
process. In Swiss hospitals, the relevant informa-
tion on patient mobility is usually not recorded in
patient charts but in a separate piece of documen-
tation used mainly by the nursing staff. A clear
trend towards early patient mobilisation may also
explain the observed low rate of at-risk medical
patients in our analysis.
medical patients patients at VTE risk
at VTE risk receiving prophylaxis
Medical condition during hospitalisation N n (%)
Ischaemic stroke 8 7 (88)
Other medical condition 10 8 (80)
Renal disease 22 15 (68)
Non-respiratory infection 26 17 (65)
Other cardiovascular disease 56 36 (64)
Acute non-infectious respiratory disease 50 31 (62)
Acute heart failure (NYHA Class III or IV) 38 23 (61)
Haematological disease 10 6 (60)
Neurological disease 17 10 (59)
Pulmonary infection 54 31 (57)
Rheumatological or inflammatory disease 4 2 (50)
Gastrointestinal or hepatobiliary disease 20 10 (50)
Active malignancy 16 7 (44)
Endocrine or metabolic disease 20 8 (40)
surgical patients patients at VTE risk
at VTE risk receiving prophylaxis
Performed type of surgery N n (%)
Curative arthroscopy 4 4 (100)
Hip replacement 54 50 (93)
Urological surgery 66 60 (91)
Gastric surgery 28 25 (89)
Hip fracture 21 18 (86)
Colon or small bowel surgery 59 50 (85)
Knee replacement 19 16 (84)
Thoracic surgery 43 36 (84)
Other orthopaedic trauma 122 102 (84)
Hepatobiliary surgery 49 40 (82)
Gynaecological surgery 5 4 (80)
Rectosigmoid surgery 28 22 (79)
Other major surgery 168 132 (79)
Vascular surgery 41 29 (71)
Major trauma but surgery not performed 73 43 (59)
Table 3
Use of ACCP recommended prophylaxis in medical and surgical patients at VTE risk.
Patients at VTE risk all surgical medical
N = 959 N = 780 N = 179
Pharmacological prophylaxis
Low-molecular-weight heparin, n (%) 644 (67) 555 (71) 89 (50)
Unfractionated heparin, n (%) 146 (15) 119 (15) 27 (15)
Other anticoagulants, n (%) 88 (9) 36 (5) 52 (29)
Vitamin K antagonist, n (%) 67 (7) 38 (5) 29 (16)
Fondaparinux, n (%) 1 (0.1) 0 (0.0) 1 (0.6)
Mechanical prophylaxis
Graduated compression stockings, n (%) 123 (13) 120 (15) 3 (2)
Intermittent pneumatic compression, n (%) 16 (2) 13 (2) 3 (2)
Foot pump, n (%) 3 (0.3) 3 (0.4) 0 (0.0)
More than one condition was allowed per patient.
Table 4
Prophylactic modalities in patients at VTE risk.
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In the context of the global ENDORSE study
[11], Switzerland ranked second worldwide in the
use of thromboprophylaxis confirming the high
quality and standard of the national health sys-
tem. Additionally, assuming similar methodology
and not taking into account potential differences
in patient populations included in the present
analysis and the previous Swiss survey [10], the
proportion of medical patients at risk for VTE re-
ceiving appropriate prophylaxis improved from
50% to 61% between 2003 and 2006. However,
there were remarkable differences between hospi-
tals in the frequency of administration of ACCP-
recommended types of prophylaxis, particularly
among at-risk medical patients, which could be
due to differences in patient characteristics, dura-
tion of hospital stay, physician awareness, avail-
ability and practicality of local screening tools
(e.g. scoring system [12]), education factors, and
reimbursement systems. The use of recom-
mended VTE prophylaxis was lower in medical
patients; only 44% of patients with active malig-
nancy, a well-recognized risk factor for VTE, re-
ceived prophylaxis. These findings are consistent
with results of the Swiss venous thromboem-
bolism registry (SWIVTER) [13], a recently pub-
lished prospective observational study in hospi-
talised Swiss patients with acute venous throm-
boembolism, which showed a lower use of throm-
boprophylaxis in at-risk medical patients (52%),
particularly in patients with cancer, acute heart or
respiratory failure and in the elderly. Possible rea-
sons for the observed low rate of prophylaxis
among patients with active malignancy in the
Swiss ENDORSE include non-prescription of
prophylaxis in patients with end-stage cancer and
short life expectancy, lack of awareness of VTE
risk, awareness of increased risk of bleeding in pa-
tients with ongoing chemotherapy, presence of
chemotherapy-induced thrombocytopenia, in-
volvement of multiple medical teams, reduced
quality of life by daily injections [14], or cost-ben-
efit concerns. In our present analysis, prophylaxis
rates were generally higher among surgical pa-
tients, although the proportion of patients receiv-
ing recommended prophylaxis varied with type of
surgery, leaving almost 30% of patients requiring
vascular procedures at VTE risk. Surprisingly,
only 59% of patients with major trauma who did
not undergo any kind of surgery, another well
known condition with a high risk for VTE, re-
ceived thromboprophylaxis.
Among patients at-risk for VTE, 7% were
classified as having a contraindication for pharma-
cological prophylaxis. However, these patients
could have received any form of the ACCP rec-
ommended mechanical prophylaxis, and therefore
do not compromise the observed lack in overall
thromboprophylaxis use.
The methodological strengths and limitations
of the survey were extensively discussed in the
global ENDORSE publication [11]. From the
local Swiss perspective, four comments should ad-
ditionally be mentioned. Firstly, the 2004 ACCP
guidelines were adapted to local practice by the
Swiss expert group and therefore represent the
most widely-accepted standard for VTE prophy-
laxis in Switzerland. Secondly, in Switzerland,
physicians certainly have different opinions about
the need and benefit of prophylaxis in patient
groups that are not defined as being at VTE risk
Patients at VTE risk all surgical medical
N = 959 N = 780 N = 179
Bleeding risk / contraindication to pharmacologic prophylaxis
Aspirin on admission, n (%) 211 (22) 142 (18) 69 (39)
NSAID on admission (excluding aspirin), n (%) 88 (9) 82 (11) 6 (3)
Significant renal impairment, n (%) 71 (7) 42 (5) 29 (16)
Bleeding at hospital admission, n (%) 26 (3) 23 (3) 3 (2)
Hepatic impairment (clinically relevant), n (%) 24 (3) 16 (2) 8 (5)
Low platelet count (<100000) per μl), n (%) 20 (2) 13 (2) 7 (4)
Intracranial haemorrhage, n (%) 11 (1) 11 (1) 0 (0.0)
Active gastroduodenal ulcer, n (%) 10 (1) 5 (0.6) 5 (3)
Known bleeding disorder, n (%) 3 (0.3) 2 (0.3) 1 (0.6)
More than one condition was allowed per patient.
NSAID: Non-steroidal anti-inflammatory drug.
Table 5
Bleeding risk and contraindications to pharmacological prophylaxis in patients
at VTE risk.
hospital surgical surgical surgical patients medical medical medical patients
patients patients at risk receiving patients patients at risk receiving
at risk prophylaxis at risk prophylaxis
N n (%) n (%) N n (%) n (%)
1 112 72 (64) 67 (93) 98 29 (30) 22 (76)
2 56 31 (55) 28 (90) 47 19 (40) 16 (84)
3 36 31 (86) 27 (87) 22 9 (41) 6 (67)
4 56 48 (86) 41 (85) 113 3 (3) 0 (0.0)
5 126 92 (73) 74 (80) 63 17 (27) 13 (77)
6 295 219 (74) 170 (78) 197 31 (16) 22 (71)
7 69 33 (48) 29 (88) 43 10 (23) 4 (40)
8 314 201 (64) 153 (76) 180 41 (23) 22 (54)
9 25 18 (72) 14 (78) 48 4 (8) 1 (25)
10 64 35 (55) 28 (80) 36 16 (44) 3 (19)
Total 1153 780 (68) 631 (81) 847 179 (21) 109 (61)
Table 6
Use of ACCP recom-
mended prophylaxis
in patients at VTE risk
by participating
hospitals.
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in the ACCP guidelines. Thirdly, the low rate of
immobilisation in the Swiss patients could have
changed the results and hamper the comparability
to the global population. Fourthly, the Swiss EN-
DORSE data might not be representative for
non-participating hospitals. Only two of the ten
participating hospitals fulfilled the minimal pa-
tient requirement criterion limiting the interpre-
tation of the results. In addition, there was a wide
between-hospital range of patients at-risk. How-
ever, our analysis included ten academic and non-
academic, public and private hospitals across
Switzerland.
In conclusion, the present analysis from the
ENDORSE study shows that a large proportion
of hospitalised Swiss patients are at-risk for VTE.
Although the overall rate of prophylaxis use in
Switzerland appeared to improve over the course
of three years [10], and compares favourably with
many other countries [11], the rate of recom-
mended thromboprophylaxis is still improvable in
medical and major trauma patients not undergo-
ing surgery. Consequently, hospital-wide strate-
gies for systematic risk factor assessment and im-
plementation of practical tools (e.g. simple scor-
ing system [12]) to ensure appropriate use of pro-
phylaxis in patients at VTE risk are required.
Moreover, the impact of implementation of vari-
ous strategies and tools on quality of prophylaxis
use should be assessed periodically.
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Figure 2
Use of ACCP-recommended prophylaxis in surgical and medical patients at VTE risk by
groups of participating hospitals.
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